Research across Cancer
Related studies from across the Cancer family.
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Systematic review and meta-analysis evaluates PRIMARY score on PSMA PET for prostate cancer detection
PRIMARY Score Finds Hidden Cancer With High Accuracy
This systematic review and meta-analysis of 1974 patients evaluated the diagnostic accuracy of the PRIMARY score on PSMA PET/CT or PET/MRI f…
A new scan reading tool catches most dangerous prostate cancers with high accuracy for men who have never had a biopsy.
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
New prostate cancer treatment shows low side effects after 5 years
This prospective phase 2 trial evaluated ultrasound-guided salvage brachytherapy with interstitial hyperthermia in 109 patients with locally…
A new treatment for recurrent prostate cancer kept 93% of patients alive at 5 years with very low serious side effects.
Online adaptive MRI-guided SBRT showed technical feasibility in intermediate-risk prostate cancer patients
New MRI-guided radiation technique works for most intermediate-risk prostate cancer patients
This Phase 2 non-randomized trial evaluated online adaptive magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy in 5…
A new radiation method delivered the right dose to tumors in 85% of patients with intermediate-risk prostate cancer. This approach uses onli…
Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
Chemo Before Prostate Surgery Linked to Better Cancer Control
This systematic review and meta-analysis evaluated neoadjuvant chemohormonal therapy (NCHT) combined with radical prostatectomy versus radic…
Patients with advanced prostate cancer may see better cancer control with chemo before surgery, though survival gains need more proof.
Narrative review on mpMRI and PSMA PET/CT for radiorecurrent prostate cancer restaging
Two imaging tests together spot prostate cancer return more accurately
This narrative review synthesizes evidence on mpMRI and PSMA-targeted PET/CT for restaging radiorecurrent prostate cancer.
For men with suspected prostate cancer return, combining two scans catches more tumors and avoids unnecessary biopsies.
Apalutamide plus ADT shows favorable survival trends in Asian and Japanese mCSPC patients
Asian Men See Real Benefit From New Prostate Drug
A Bayesian post hoc analysis of a phase 3 trial in Asian (n=221) and Japanese (n=51) patients with metastatic castration-sensitive prostate …
New analysis confirms the drug works well for Asian and Japanese patients, helping men with advanced prostate cancer live longer and delay p…